Study #2015-0555
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)
Study Status
Closed
Treatment Agent
Principal Investigator
Swaminathan P. Iyer
Description
The goal of this clinical research study is to find the highest tolerable dose of pralatrexate (Folotyn) that can be given in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with PTCL.
General Information
Treatment Location: N/A
Sponsor: N/A
Study Status
IRB Review and Approval Date: 02/09/2016
Recruitment Status: Closed
Projected Accrual: N/A
Resources and Links
Information and next steps
Disease:
Study phase:
Phase I
Physician name:
Swaminathan P. Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789